Document:

Exhibit
10.6

 

REGISTRATION
RIGHTS AGREEMENT

 

REGISTRATION
RIGHTS AGREEMENT (this “Agreement”), dated as of December 29, 2017, by and among MedyMatch Technology
Ltd., a company incorporated under the laws of the State of Israel, with headquarters located at 76 Yigal Alon Street, Floor 5,
Tel Aviv, Israel 6706701 (the “Company”), and the investors listed on the Schedule of Purchasers attached hereto
(each, a “Purchaser” and collectively, the “Purchasers”).

 

WHEREAS:

 

A. In
connection with the Securities Purchase Agreement by and among the parties hereto of even date herewith (the “Securities
Purchase Agreement”), the Company has agreed, upon the terms and subject to the conditions of the Securities Purchase
Agreement, to issue and sell to each Purchaser, secured convertible promissory notes (“Notes”) convertible
into Company’s Ordinary Shares, par value NIS 0.01 per share (the “Ordinary Shares”) (on conversion of
principal and interest on the Notes, collectively, the “Conversion Shares”).

 

B. The
Company has undertaken to use its commercially reasonable efforts to close the Qualified Offering (as defined in the Securities
Purchase Agreement) within not later than the later of (i) June 30, 2018, and (ii) six (6) months of the date of this Agreement
and contemporaneously therewith to cause the Conversion Shares to be registered for resale by the Purchasers on a Form S-1 registration
statement to be filed with the SEC.

 

C. In
accordance with the terms of the Securities Purchase Agreement, the Company has agreed to provide certain registration rights
as described herein, under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor
statute (collectively, the “1933 Act”), and applicable state securities laws.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and each of the Purchasers hereby agree as follows:

 

1. Definitions.

 

Capitalized
terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement.
As used in this Agreement, the following terms shall have the following meanings:

 

(a) “Additional
Effective Date” means the date the Additional Registration Statement is declared effective by the SEC.

 

(b) “Additional
Effectiveness Deadline” means the date which is the earlier of (x) (i) in the event that the Additional Registration
Statement is not subject to a full review by the SEC, twenty (20) calendar days after the earlier of the Additional Filing Date
and the Additional Filing Deadline or (ii) in the event that the Additional Registration Statement is subject to a full review
by the SEC, sixty (60) calendar days after the earlier of the Additional Filing Date and the Additional Filing Deadline and (y)
the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by
the SEC that such Additional Registration Statement will not be reviewed or will not be subject to further review; provided, however,
that if the Additional Effectiveness Deadline falls on a Saturday, Sunday or other day that the SEC is closed for business, the
Additional Effectiveness Deadline shall be extended to the next Business Day on which the SEC is open for business.

 

    

     

    

 

(c) “Additional
Filing Date” means the date on which the Additional Registration Statement is filed with the SEC.

 

(d) “Additional
Filing Deadline” means if Additional Registrable Securities are required to be included in any Additional Registration
Statement, thirty (30) days after the date substantially all of the Registrable Securities registered under the immediately preceding
Registration Statement are sold.

 

(e) “Additional
Registrable Securities” means, any capital stock of the Company issued or issuable with respect to the Notes and Conversion
Shares as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise all without regard
to any limitations on conversion of the Notes.

 

(f) “Additional
Registration Statement” means a registration statement or registration statements of the Company filed under the 1933
Act covering the resale of any Additional Registrable Securities.

 

(g) “Additional
Required Registration Amount” means (I) any Additional Registrable Securities not previously included on a Registration
Statement, all subject to adjustment as provided in Section 2(f) or (II) such other amount as may be permitted by the staff of
the SEC pursuant to Rule 415, without regard to any limitations on conversion of Notes.

 

(h) “Business
Day” means any day except any Saturday, Sunday and any day which is a federal legal holiday in the United States, or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

(i) “Closing
Date” shall mean the initial Closing Date as defined in the Securities Purchase Agreement.

 

(j) “Effective
Date” means the Initial Effective Date and the Additional Effective Date, as applicable.

 

(k) “Effectiveness
Deadline” means the Initial Effectiveness Deadline and the Additional Effectiveness Deadline, as applicable.

 

(l) “Eligible
Market” means The New York Stock Exchange, Inc., the NYSE MKT LLC, The NASDAQ Capital Market, The NASDAQ Global Select
Market, The Nasdaq Global Market, the OTC Bulletin Board, the OTCQB or the OTCQX
(or any successors to any of the foregoing).

 

(m) “Filing
Deadline” means the Initial Filing Deadline and the Additional Filing Deadline, as applicable.

 

(n) “Initial
Effective Date” means the date that the Initial Registration Statement has been declared effective by the SEC.

 

(o) “Initial
Effectiveness Deadline” means the first closing of the Qualified Offering.

 

(p) “Initial
Filing Date” means the date on which the Initial Registration Statement is filed with the SEC.

 

    - 2 -

     

    

 

(q) “Initial
Filing Deadline” means the date on which the initial registration statement to be employed in connection with the Qualified
Offering is filed with the SEC.

 

(r) “Initial
Registrable Securities” means (i) the Conversion Shares issuable upon conversion of the Notes issued in connection with
the Closing, (ii) the Ordinary Shares described on the Schedule of Investors under the heading “Private Purchase Shares”,
and (iii) any capital stock of the Company issued or issuable with respect to the Notes and Conversion Shares and Private Purchase
Shares as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise without regard
to any limitations on conversion of the Notes including interest which could accrue through six months after the issue date of
the Notes; but excluding any Ordinary Shares held by or issuable to Exigent.

 

(s) “Initial
Registration Statement” means a registration statement or registration statements of the Company filed under the 1933
Act covering the resale of the Initial Registrable Securities (which may be the registration statement of the Company for the
Qualified Offering).

 

(t) “Initial
Required Registration Amount” means the maximum number of Conversion Shares which may be issued upon conversion of the
Notes.

 

(u) “Investor”
means a Purchaser (including Palladium Capital Advisors LLC with respect to Notes issued in lieu of cash placement agent fees),
the holders of Ordinary Shares described on the Schedule of Investors under the heading “Private Purchase Shares”,
or any transferee or assignee thereof to whom a Purchaser assigns its rights under this Agreement and who agrees to become bound
by and who otherwise complies with the provisions of this Agreement in accordance with Section 9 and any transferee or assignee
thereof to whom a transferee or assignee assigns its rights under this Agreement and who agrees to become bound by the provisions
of this Agreement in accordance with Section 9.

 

(v) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization
and a government or any department or agency thereof.

 

(w) “Principal
Market” means Eligible Market which is the primary market for the trading or listing of the Ordinary Shares.

 

(x) “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing
one or more Registration Statements (as defined below) in compliance with the 1933 Act and pursuant to Rule 415, and the declaration
or ordering of effectiveness of such Registration Statement(s) by the SEC.

 

(y) “Registrable
Securities” means the initial Registrable Securities and the Additional Registrable Securities; provided, however,
that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain
the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration
Statement with respect to the sale of such Registrable Securities has been declared effective by the Commission under the Securities
Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement,
(b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible
for resale without volume or manner-of-sale restrictions and without the requirement for the Company to be in compliance with
the current public information requirement under Rule 144, as determined by counsel to the Company including pursuant to a written
opinion letter to such effect addressed, delivered and acceptable to the Transfer Agent.

 

    - 3 -

     

    

 

(z) “Registration
Statement” means the Initial Registration Statement and the Additional Registration Statement, as applicable.

 

(aa)“Required
Holders” means holders of at least a majority of the issued and issuable Registrable Securities, which must include
South Florida Biotech Ventures, LLC for so long as South Florida Biotech Ventures, LLC hold Registrable Securities acquired for
not less than $1,000,000.

 

(bb)“Required
Registration Amount” means either the Initial Required Registration Amount or the Additional Required Registration Amount,
as applicable.

 

(cc)“Rule
415” means Rule 415 promulgated under the 1933 Act or any successor rule providing for offering securities on a continuous
or delayed basis.

 

(dd)“SEC”
means the United States Securities and Exchange Commission.

 

(ee)“Trading
Day” means any day on which the Ordinary Shares is traded on the Principal Market, or, if the Principal Market is not
the principal trading market for the Ordinary Shares, then on the principal securities exchange or securities market on which
the Ordinary Shares is then traded; provided that “Trading Day” shall not include any day on which the Ordinary Shares
is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Ordinary Shares is suspended from
trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance
the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time).

 

2. Registration.

 

(a) Initial
Mandatory Registration. Promptly following the Closing Date, the Company shall prepare, and, as soon as practicable but in
no event later than the Initial Filing Deadline, file with the SEC the Initial Registration Statement on Form S-1 (or such other
form as is available for such a registration on another appropriate form reasonably acceptable to the Required Holders, subject
to the provisions of Section 2(e)) covering the resale of all of the Initial Registrable Securities. The Initial Registration
Statement prepared pursuant hereto shall register for resale at least the number of Ordinary Shares equal to the Initial Required
Registration Amount determined as of the date the Initial Registration Statement is initially filed with the SEC, subject to adjustment
as provided in Section 2(f). The Initial Registration Statement shall contain (except if otherwise directed by the Required Holders)
the “Plan of Distribution” and “Selling Shareholders” sections in substantially the form
attached hereto as Exhibit B, with such modifications as may be required by law or in response to comments of the staff
of the SEC. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement declared effective
by the SEC as soon as practicable, but in no event later than the Initial Effectiveness Deadline. By 9:30 a.m., New York time
on the second Business Day following the Initial Effective Date, the Company shall file with the SEC in accordance with Rule 424
under the 1933 Act the final prospectus to be used in connection with sales pursuant to such Initial Registration Statement.

 

    - 4 -

     

    

 

(b) Additional
Mandatory Registrations. The Company shall prepare, and, as soon as practicable but in no event later than the Additional
Filing Deadline, file with the SEC an Additional Registration Statement on Form S-3 covering the resale of all of the Additional
Registrable Securities not previously registered on an Additional Registration Statement hereunder. To the extent the staff of
the SEC does not permit the Additional Required Registration Amount to be registered on an Additional Registration Statement,
the Company shall file Additional Registration Statements within ten Business Days of each rejection by the SEC trying to register
on each such Additional Registration Statement the maximum number of remaining Additional Registrable Securities until the Additional
Required Registration Amount has been registered with the SEC; provided that after two rejections by the SEC of Additional Registration
Statements, the Company shall not be required to file Additional Registration Statements more frequently than once per sixty (60)
day period commencing subsequent to the second rejection. In the event that Form S-3 is unavailable for such a registration, the
Company shall use Form S-1 or such other form as is available for such a registration on another appropriate form reasonably acceptable
to the Required Holders, subject to the provisions of Section 2(e). Each Additional Registration Statement prepared pursuant hereto
shall seek to register for resale at least that number of Ordinary Shares equal to the Additional Required Registration Amount
determined as of the date such Additional Registration Statement is initially filed with the SEC, subject to adjustment
as provided in Section 2(f). Each Additional Registration Statement shall contain (except if otherwise directed by the Required
Holders) the “Plan of Distribution” and “Selling Shareholders” sections in substantially
the form attached hereto as Exhibit B with such modifications as may be required by law or in response to comments of the
staff of the SEC. The Company shall use its commercially reasonable efforts to have each Additional Registration Statement declared
effective by the SEC as soon as practicable, but in no event later than the Additional Effectiveness Deadline. By 9:30 a.m., New
York time on the Business Day following the Additional Effective Date, the Company shall file with the SEC in accordance with
Rule 424 under the 1933 Act the final prospectus to be used in connection with sales pursuant to such Additional Registration
Statement.

 

(c) Allocation
of Registrable Securities. The initial number of Registrable Securities included in any Registration Statement and any increase
or decrease in the number of Registrable Securities included therein shall be allocated pro rata among the Investors based on
the number of Registrable Securities held by each Investor at the time the Registration Statement covering such initial number
of Registrable Securities or increase or decrease thereof is declared effective by the SEC. In the event that an Investor sells
or otherwise transfers any of such Investor’s Registrable Securities, subject to Section 9, each transferee shall be allocated
a pro rata portion of the then remaining number of Registrable Securities included in such Registration Statement for such transferor.
Any Ordinary Shares included in a Registration Statement and which remain allocated to any Person which ceases to hold any Registrable
Securities covered by such Registration Statement shall be allocated to the remaining Investors, pro rata based on the number
of Registrable Securities then held by such Investors which are covered by such Registration Statement. In no event shall the
Company include any securities other than Registrable Securities on any Registration Statement without the prior written consent
of the Required Holders.

 

(d) Legal
Counsel. Subject to Section 5 hereof, the Required Holders shall have the right to select one legal counsel to review and
oversee any registration pursuant to this Section 2 (“Legal Counsel”), which shall be Grushko & Mittman,
P.C., or such other counsel as thereafter designated by the Required Holders. The Company and Legal Counsel shall reasonably cooperate
with each other in performing the Company’s obligations under this Agreement at the Company’s cost and expense, provided
that the Company shall not be obligated to pay more than $5,000 in the aggregate pursuant to this paragraph.

 

(e) Ineligibility
for Form S-3. In the event that the Company or the nature of the offering do not qualify for the use of Form S-3 for the registration
of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on
Form S-1 or another appropriate form reasonably acceptable to the Required Holders and (ii) undertake to register the Registrable
Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration
Statement then in effect until such time as any such Registration Statement on Form S-3 filed by the Company covering the Registrable
Securities has been declared effective by the SEC.

 

    - 5 -

     

    

 

(f) Sufficient
Number of Shares Registered. In the event the number of shares available under a Registration Statement filed pursuant to
Section 2(a) or Section 2(b) is insufficient to cover the Required Registration Amount of Registrable Securities required to be
covered by such Registration Statement or an Investor’s allocated portion of the Registrable Securities pursuant to Section
2(c), the Company shall amend the applicable Registration Statement, or file a new Registration Statement (on the short form available
therefor, if applicable), or both, so as to cover at least the Required Registration Amount as of the Trading Day immediately
preceding the date of the filing of such amendment or new Registration Statement, in each case, as soon as practicable, but in
any event not later than fifteen (15) days after the necessity therefor arises. The Company shall use its commercially reasonable
efforts to cause such amendment and/or new Registration Statement to become effective as soon as practicable following the filing
thereof. For purposes of the foregoing provision, the number of shares available under a Registration Statement shall be deemed
“insufficient to cover all of the Registrable Securities” if at any time the number of Ordinary Shares available for
resale under the Registration Statement is less than the Required Registration Amount.

 

(g) Effect
of Failure to File and Obtain and Maintain Effectiveness of Registration Statement. If a Registration Statement covering all
of the Registrable Securities required to be covered thereby and required to be filed by the Company pursuant to this Agreement
is (A) not filed with the SEC on or before the applicable Filing Deadline (a “Filing Failure”) or (B) not declared
effective by the SEC on or before the applicable Effectiveness Deadline, (an “Effectiveness Failure”) or (ii)
on any day after the applicable Effective Date, sales of all of the Registrable Securities required to be included on such Registration
Statement cannot be made (other than during an Allowable Grace Period (as defined in Section 3(r)) pursuant to such Registration
Statement or otherwise (including, without limitation, because of the suspension of trading or any other limitation imposed by
an Eligible Market, a failure to keep such Registration Statement effective, a failure to disclose such information as is necessary
for sales to be made pursuant to such Registration Statement, a failure to register a sufficient number of Ordinary Shares or
a failure to maintain the listing of the Ordinary Shares) (a “Maintenance Failure” and collectively with a
Filing Failure and an Effectiveness Failure, the “Failures” and each a “Failure”), then,
as partial relief for the damages to any holder by reason of a Failure (which remedy shall not be exclusive of any other remedies
available at law or in equity), the Company shall pay to each holder of Registrable Securities relating to such Registration Statement
an amount in cash equal to one percent (1%) of the aggregate Subscription Amount (as defined in the Securities Purchase Agreement)
of such Investor’s Registrable Securities whether or not included in such Registration Statement, on each of the following
dates: (i) the day of a Filing Failure; (ii) the day of an Effectiveness Failure; (iii) the initial day of a Maintenance Failure;
(iv) on the thirtieth day after the date of a Filing Failure and every thirtieth day thereafter (pro-rated for periods totaling
less than thirty days) until such Filing Failure is cured; (v) on the thirtieth day after the date of an Effectiveness Failure
and every thirtieth day thereafter (pro-rated for periods totaling less than thirty days) until such Effectiveness Failure is
cured; and (vi) on the thirtieth day after the initial date of a Maintenance Failure and every thirtieth day thereafter (pro-rated
for periods totaling less than thirty days) until such Maintenance Failure is cured; provided however, in the event that there
shall be more than one Failure occurring simultaneously, then 1% shall apply in the aggregate (e.g., during any single or multiple
Failure, 1% shall be due, however 1% shall not be due “per Failure” if the Failures are simultaneous and for so long
as such Failures are simultaneous). The payments to which a holder shall be entitled pursuant to this Section 2(g) are referred
to herein as “Registration Delay Payments.” Registration Delay Payments shall be paid on the earlier of (I)
the dates set forth above and (II) the third Business Day after the event or failure giving rise to the Registration Delay Payments
is cured. In the event the Company fails to make Registration Delay Payments in a timely manner, such Registration Delay Payments
shall bear interest at the rate of one percent (1%) per month (prorated for partial months) until paid in full. Notwithstanding
anything to the contrary contained herein, Registration Delay Payments shall (i) not, in the aggregate, exceed seven percent (7%)
of the aggregate Purchase Price, (ii) cease to accrue as soon as all of the Registrable Securities may be sold pursuant to Rule
144 without volume or manner-of-sale restrictions and without the requirement for the Company to be in compliance with the current
public information requirement under Rule 144, as determined by counsel to the Company including pursuant to a written opinion
letter to such effect addressed, delivered and acceptable to the Transfer Agent, and (ii) cease to accrue upon the termination
of the Registration Period (as defined below).

 

    - 6 -

     

    

 

(h) Limitation
on Other Registration Statements. Except in connection with the Qualified Offering, the Company shall not file another registration
statement under the 1933 Act prior to the earlier of (i) date that the Initial Registration Statement is declared effective
by the SEC and (ii) the Initial Registration Statement has been effective in the aggregate for not less than 180 days after
the closing of the Qualified Offering; provided that, this Section 2(h) shall not prevent the Company from filing a registration
statement on Form S-4 or Form S-8 with the SEC at any time beginning thirty (30) days after the Initial Effective Date.

 

3. Related
Obligations.

 

At
such time as the Company is obligated to file a Registration Statement with the SEC pursuant to Section 2(a), 2(b), 2(e) or 2(f),
the Company will use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance
with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:

 

(a) The
Company shall promptly prepare and file with the SEC a Registration Statement with respect to the Registrable Securities and use
its commercially reasonable efforts to cause such Registration Statement relating to the Registrable Securities to become effective
as soon as practicable after such filing (but in no event later than the Effectiveness Deadline). The Company shall keep each
Registration Statement effective pursuant to Rule 415 at all times until the earlier of (i) the date that is two (2) years after
the Conversion Date, or (ii) the date on which the Investors shall have sold all of the Registrable Securities required to be
covered by such Registration Statement (the “Registration Period”). The Company shall ensure that each Registration
Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein
(in the case of prospectuses, in the light of the circumstances in which they were made) not misleading. The term “commercially
reasonable efforts” shall mean, among other things, that the Company shall submit to the SEC, within two (2) Business Days
after the later of the date that (i) the Company learns that no review of a particular Registration Statement will be made by
the staff of the SEC or that the staff has no further comments on a particular Registration Statement, as the case may be, and
(ii) a request for acceleration of effectiveness of such Registration Statement to a time and date not later than two (2) Business
Days after the submission of such request. The Company shall respond in writing to comments made by the SEC in respect of a Registration
Statement as soon as practicable but in no event later than fifteen (15) days after the receipt of comments by or notice from
the SEC that an amendment is required in order for a Registration Statement to be declared effective.

 

(b) The
Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration
Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to
Rule 424 promulgated under the 1933 Act, as may be necessary to keep such Registration Statement effective at all times during
the Registration Period, subject to Section 3(r), and, during such period, comply with the provisions of the 1933 Act with respect
to the disposition of all Registrable Securities of the Company covered by such Registration Statement until such time as all
of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition by the seller
or sellers thereof as set forth in such Registration Statement. In the case of amendments and supplements to a Registration Statement
which are required to be filed pursuant to this Agreement (including pursuant to this Section 3(b)) by reason of the Company filing
a report on Form 10-K, Form 10-Q, Form 8-K or any analogous report under the Securities Exchange Act of 1934, as amended (the
“1934 Act”), the Company shall have incorporated such report by reference into such Registration Statement,
if applicable, or shall file such amendments or supplements with the SEC on the same day on which the 1934 Act report is filed
which created the requirement for the Company to amend or supplement such Registration Statement.

 

    - 7 -

     

    

 

(c) The
Company shall (A) permit Legal Counsel to review and comment upon (i) a Registration Statement at least three (3) Business Days
prior to its filing with the SEC and (ii) all amendments and supplements to all Registration Statements (except for those filed
by reason of the Company filing Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and
any similar or successor reports) within a reasonable number of days prior to their filing with the SEC, (B) permit each Investor
to review and comment on the “Plan of Distribution” and “Selling Shareholders” sections of the Registration
Statement and all amendments and supplements to the Registration Statement to the extent any changes are made to those sections,
and (C) not file any Registration Statement or amendment or supplement thereto in a form to which Legal Counsel reasonably objects;
provided however, that if the delay in filing the Registration Statement is due to Legal Counsel’s or an Investor’s
unreasonable objections (and unreasonable refusal to allow the Company to file the Registration Statement) or unreasonable delay
then in such event, no Failure (or similar event that triggers a Registration Delay Payment) shall be deemed to have occurred
with such delay arising from Legal Counsel’s or such Investor’s unreasonable objections or delay. The Company shall
not submit a request for acceleration of the effectiveness of a Registration Statement or any amendment or supplement thereto
without the prior approval of Legal Counsel, which consent shall not be unreasonably withheld or delayed; provided however, that
if the delay in filing the effectiveness of the Registration Statement is due to Legal Counsel’s unreasonable objections
(and unreasonable refusal to allow the Registration Statement to become effective) or unreasonable delay then in such event, no
Effectiveness Failure (or similar event that triggers a Registration Delay Payment) shall be deemed to have occurred. The Company
shall furnish to Legal Counsel, without charge, copies of any correspondence from the SEC or the staff of the SEC to the Company
or its representatives relating to any Registration Statement. The Company shall reasonably cooperate with Legal Counsel in performing
the Company’s obligations pursuant to this Section 3.

 

(d)
No securities of the Company may be included for registration in a Registration Statement except for the Registrable Securities.

 

(e) The
Company shall use its commercially reasonable efforts to (i) register and qualify, unless an exemption from registration and qualification
applies, the resale by Investors of the Registrable Securities covered by a Registration Statement under such other securities
or “blue sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions
such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary
to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain
such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably
necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company
shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where
it would not otherwise be required to qualify but for this Section 3(e), (y) subject itself to any material tax in any such jurisdiction,
or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel
and each Investor who holds Registrable Securities of the receipt by the Company of any notification with respect to the suspension
of the registration or qualification of any of the Registrable Securities for sale under the securities or “blue sky”
laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding
for such purpose.

 

    - 8 -

     

    

 

(f) The
Company shall notify Legal Counsel in writing of the happening of any event, as promptly as practicable but not later than the
first Trading Day after becoming aware of such event, (i) as a result of which the prospectus included in a Registration Statement,
as then in effect, includes an untrue statement of a material fact or omission to state a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading
(provided that in no event shall such notice contain any material, nonpublic information), or (ii) that results in the lack of
effectiveness of any Registration Statement, and, subject to Section 3(r), promptly prepare a supplement or amendment to such
Registration Statement to correct such untrue statement or omission, or lack of effectiveness of any Registration Statement, and
deliver such number of copies of such supplement or amendment to Legal Counsel and each Investor as Legal Counsel or such Investor
may reasonably request. The Company shall also promptly notify Legal Counsel in writing (i) when a prospectus or any prospectus
supplement or post-effective amendment has been filed, and when a Registration Statement or any post-effective amendment has become
effective (notification of such effectiveness shall be delivered to Legal Counsel and each Investor by facsimile or email on the
same day of such effectiveness and by overnight mail), (ii) of any request by the SEC for amendments or supplements to a Registration
Statement or related prospectus or related information, and (iii) of the Company’s reasonable determination that a post-effective
amendment to a Registration Statement would be appropriate. On the Trading Day following the date any post-effective amendment
has become effective, the Company shall file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus
to be used in connection with sales pursuant to such Registration Statement.

 

(g) The
Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction
and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest practicable
moment and to notify Legal Counsel and each Investor who holds Registrable Securities being sold of the issuance of such order
and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.

 

(h) If
any Investor is required by the SEC to be described in the Registration Statement as an underwriter or an Investor reasonably
believes that it should be identified as an underwriter of Registrable Securities in the Registration Statement and the Registration
Statement is so modified, at the reasonable request of such Investor, the Company shall furnish to such Investor on the date of
the effectiveness of the Registration Statement and thereafter from time to time on such dates as an Investor may reasonably request
(i) a letter, dated such date, from the Company’s independent certified public accountants in form and substance as is customarily
given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the Investors,
and (ii) an opinion, dated as of such date, of counsel representing the Company for purposes of such Registration Statement, in
form, scope and substance as is customarily given in an underwritten public offering, addressed to the Investors.

 

(i) Subject
to the provisions of Section 3(s) below, if any Investor (other than an Investor that agrees to withdraw as a selling shareholder
under the Registration Statement pursuant to such Section 3(s)) is required under applicable securities laws to be described in
the Registration Statement as an underwriter or an Investor agrees that it could reasonably be deemed to be an underwriter of
Registrable Securities, the Company shall make available for inspection by (i) such Investor, (ii) one law firm retained by such
Investors and (iii) one firm of accountants or other agents retained by such Investors (collectively, the “Inspectors”),
all pertinent financial and other records, and pertinent corporate documents and properties of the Company (collectively, the
“Records”), as shall be reasonably deemed necessary by each Inspector, and cause the Company’s officers,
directors and employees to supply all information which any Inspector may reasonably request; provided, however, that each Investor
hereby agrees and each Inspector shall agree to hold in strict confidence and shall not make any disclosure (except in the case
of an Inspector, to an Investor) or use of any Record or other information which the Company determines in good faith to be confidential,
and of which determination the Inspectors are so notified, unless (a) the disclosure of such Records is necessary to avoid or
correct a misstatement or omission in any Registration Statement or is otherwise required under the 1933 Act, (b) the release
of such Records is ordered pursuant to a final, non-appealable subpoena or order from a court or government body of competent
jurisdiction, or (c) the information in such Records has been made generally available to the public other than by disclosure
in violation of this Agreement. Each Investor agrees that information obtained by it as a result of such inspections shall be
deemed confidential and shall not be used by it or its advisors or related parties as the basis for any market transactions in
the Company securities unless and until such information is made generally available to the public. Each Investor agrees that
it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent jurisdiction
or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate action
to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential. Nothing herein (or in any other
confidentiality agreement between the Company and any Investor) shall be deemed to limit the Investors’ ability to sell
Registrable Securities in a manner which is otherwise consistent with applicable laws and regulations.

 

    - 9 -

     

    

 

(j) The
Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless
(i) disclosure of such information is necessary to comply with federal or state securities laws or Eligible Market requirements,
(ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement,
(iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental
body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure
in violation of this Agreement or any other agreement. The Company agrees that it shall, upon learning that disclosure of such
information concerning an Investor is sought in or by a court or governmental body of competent jurisdiction or through other
means, give prompt written notice to such Investor and allow such Investor a reasonable period of time, at the Investor’s
expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

(k) The
Company shall use its commercially reasonable efforts either to (i) cause all of the Registrable Securities covered by a Registration
Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then
listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange or (ii) secure
the inclusion for quotation of all of the Registrable Securities on the Principal Market or (iii) if, despite the Company’s
commercially reasonable efforts, the Company is unsuccessful in satisfying the preceding clauses (i) and (ii), to secure the inclusion
for quotation on another Eligible Market for such Registrable Securities and, without limiting the generality of the foregoing,
to use its commercially reasonable efforts to arrange for at least two market makers to register with the Financial Industry Regulatory
Authority, Inc. (“FINRA”) as such with respect to such Registrable Securities. The Company shall pay all fees
and expenses in connection with satisfying its obligation under this Section 3(k).

 

(l) The
Company shall reasonably cooperate with the Investors who hold Registrable Securities being offered and, to the extent applicable,
facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable
Securities to be offered pursuant to a Registration Statement and enable such certificates to be in such denominations or amounts,
as the case may be, as the Investors may reasonably request and registered in such names as the Investors may request.

 

(m) If
requested by an Investor or Investors holding individually or in the aggregate at least five percent (5%) of the outstanding Registrable
Securities, the Company shall as soon as practicable (i) incorporate in a prospectus supplement or post-effective amendment such
information as such one or more Investors reasonably request to be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold,
the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering;
(ii) make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to
be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration
Statement if reasonably requested by an Investor holding any Registrable Securities.

 

    - 10 -

     

    

 

(n) The
Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by a Registration Statement
to be registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition
of such Registrable Securities on an Eligible Market.

 

(o) The
Company shall make generally available to its security holders as soon as practical, but not later than ninety (90) days after
the close of the period covered thereby, an earnings statement (in form complying with, and in the manner provided by, the provisions
of Rule 158 under the 1933 Act) covering a twelve-month period beginning not later than the first day of the Company’s fiscal
quarter next following the applicable Effective Date of a Registration Statement.

 

(p) The
Company shall otherwise use its best efforts to comply in all material respects with all applicable rules and regulations of the
SEC in connection with any registration hereunder.

 

(q) Within
two (2) Business Days after a Registration Statement which covers Registrable Securities is ordered effective by the SEC, the
Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investors whose Registrable Securities are included in such Registration Statement) confirmation that such
Registration Statement has been declared effective by the SEC in the form attached hereto as Exhibit A.

 

(r) Notwithstanding
anything to the contrary herein, at any time after the Effective Date, the Company may delay the disclosure of material, non-public
information concerning the Company the disclosure of which at the time is not, in the good faith opinion of the Board of Directors
of the Company, in the best interest of the Company, otherwise required (a “Grace Period”); provided, that
the Company shall promptly (i) notify the Investors in writing of the existence of material, non-public information giving rise
to a Grace Period (provided that in each notice the Company will not disclose the content of such material, non-public information
to the Investors) and the date on which the Grace Period will begin, and (ii) notify the Investors in writing of the date on which
the Grace Period ends; and, provided further, that no Grace Period shall exceed fifteen (15) consecutive Trading Days and during
any three hundred sixty five (365) day period such Grace Periods shall not exceed an aggregate of fifty (50) Trading Days and
the first day of any Grace Period must be at least five (5) Trading Days after the last day of any prior Grace Period and no such
Grace Period shall apply until the Initial Registration Statement has been effective for at least 180 days after the initial closing
of the Qualified Offering (each, an “Allowable Grace Period”). For purposes of determining the length of a
Grace Period above, the Grace Period shall begin on and include the date the Investors receive the notice referred to in clause
(i) and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii) and the date
referred to in such notice. The provisions of Section 2(a), 2(g), 3(a) and 3(b) hereof shall not be applicable during the period
of any Grace Period. Upon expiration of the Grace Period, the Company shall again be bound by the first sentence of Section 3(f)
with respect to the information giving rise thereto unless such material, non-public information is no longer applicable. Notwithstanding
anything to the contrary, the Company shall cause its transfer agent to deliver unlegended Ordinary Shares to a transferee of
an Investor in accordance with the terms of the Securities Purchase Agreement in connection with any sale of Registrable Securities
with respect to which an Investor has entered into a contract for sale, prior to the Investor’s receipt of the notice of
a Grace Period and which sale has not yet settled.

 

    - 11 -

     

    

 

(s) Except
as required by the SEC or by applicable law, neither the Company nor any Subsidiary or affiliate thereof shall identify any Investor
as an underwriter in any public disclosure or filing with the SEC, the Principal Market or any Eligible Market and any Investor
being deemed an underwriter by the SEC shall not relieve the Company of any obligations it has under this Agreement or any other
Transaction Document (as defined in the Securities Purchase Agreement); provided, however, that the foregoing shall
not prohibit the Company from including the disclosure found in the “Plan of Distribution” section attached hereto
as Exhibit B in the Registration Statement. If the Company is required by the SEC or by applicable law to identify any
Investor as an underwriter in any public disclosure or filing with the SEC, the Principal Market or any Eligible Market, prior
to so identifying any such Investor, the Company shall promptly notify each such Investor of the legal requirement and give each
such Investor a reasonable opportunity to persuade the applicable regulator that said disclosure is not required. If the applicable
Investors are unable to eliminate the legal requirement to be identified as an underwriter, the applicable Investor shall have
five (5) Business Days from such notice (which five (5) Business Days shall constitute an additional Allowable Grace Period independent
of and not aggregating with any other Grace Period), to consent to such disclosure or to agree to withdraw as a selling shareholder
under the Registration Statement. If an Investor agrees to withdraw as a selling shareholder under the Registration Statement,
the Company shall not be responsible for any such Failures with respect to any such Investor.

 

(t) Neither
the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries,
on or after the date of this Agreement, enter into any agreement with respect to its securities, that would prevent the Company
from performing its obligations hereunder.

 

(u) The
Company may require each Investor to furnish to the Company a statement as to the number of Ordinary Shares of the Company beneficially
owned by such Holder and, if required by the SEC, the natural persons thereof that have voting and dispositive control over the
shares.

 

4. Obligations
of the Investors.

 

(a) At
least five (5) Business Days prior to the first anticipated Filing Date of a Registration Statement, the Company shall notify
each Investor in writing of the information the Company requires from each such Investor if such Investor elects to have any of
such Investor’s Registrable Securities included in such Registration Statement. It shall be a condition precedent to the
obligations of the Company to complete any registration pursuant to this Agreement with respect to the Registrable Securities
of a particular Investor that such Investor shall timely furnish to the Company such information regarding itself, the Registrable
Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required
by the Company to effect and maintain the effectiveness of the registration of such Registrable Securities and shall timely execute
such documents in connection with such registration as the Company may reasonably request.

 

(b) Each
Investor, by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably
requested by the Company in connection with the preparation and filing of any Registration Statement hereunder, unless such Investor
has notified the Company in writing of such Investor’s election to exclude all of such Investor’s Registrable Securities
from such Registration Statement.

 

(c) Each
Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section
3(g) or the first sentence of 3(f) (a “No Sale Notice”), such Investor will immediately discontinue disposition of
Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until such Investor’s
receipt of copies of the supplemented or amended prospectus as contemplated by Section 3(g) or the first sentence of 3(f) or receipt
of notice that no supplement or amendment is required. Notwithstanding anything to the contrary, the Company shall cause its transfer
agent to deliver unlegended Ordinary Shares to a transferee of an Investor in accordance with the terms of the Securities Purchase
Agreement in connection with any sale of Registrable Securities with respect to which an Investor has entered into a contract
for sale prior to the Investor’s receipt of a notice from the Company of the happening of any event of the kind described
in Section 3(g) or the first sentence of 3(f) and which sale has not yet settled.

 

    - 12 -

     

    

 

(d) Each
Investor covenants and agrees that it will comply with the prospectus delivery requirements of the 1933 Act as applicable to it
or an exemption therefrom in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

5. Expenses
of Registration.

 

All
reasonable expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or
qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees,
printers and accounting fees, and fees and disbursements of counsel for the Company shall be paid by the Company. The Company
shall also reimburse the Investors for the reasonable fees and disbursements of Legal Counsel in connection with registration,
filing or qualification pursuant to Sections 2 and 3 of this Agreement which amount shall be limited to $5,000 in the aggregate.

 

6. Indemnification.

 

In
the event any Registrable Securities are included in a Registration Statement under this Agreement:

 

(a) To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, the
directors, officers, partners, members, employees, agents, representatives of, and each Person, if any, who controls any Investor
within the meaning of the 1933 Act or the 1934 Act (each, an “Indemnified Person”), against any losses, claims,
damages, liabilities, judgments, fines, penalties, charges, costs, reasonable attorneys’ fees, amounts paid in settlement
or expenses, joint or several (collectively, “Claims”), incurred in investigating, preparing or defending any
action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental,
administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party
is or may be a party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such
Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any
untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto
or in any filing made in connection with the qualification of the offering under the securities or other “blue sky”
laws of any jurisdiction in which Registrable Securities are offered (“Blue Sky Filing”), or the omission or
alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
(ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus if used prior
to the effective date of such Registration Statement, or contained in the final prospectus (as amended or supplemented, if the
Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any
material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein
were made, not misleading, (iii) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act, any other law,
including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of
the Registrable Securities pursuant to a Registration Statement or (iv) any violation of this Agreement (the matters in the foregoing
clauses (i) through (iv) being, collectively, “Violations”). Subject to Section 6(c), the Company shall reimburse
the Indemnified Persons, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable
expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary
contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Indemnified
Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in
writing to the Company by such Indemnified Person for such Indemnified Person expressly for use in connection with the preparation
of the Registration Statement or any such amendment thereof or supplement thereto; and (ii) shall not apply to amounts paid in
settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not
be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made
by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investors pursuant
to Section 9.

 

    - 13 -

     

    

 

(b) In
connection with any Registration Statement in which an Investor is participating, each such Investor agrees to severally and not
jointly indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company,
each of its directors, each of its officers who signs the Registration Statement and each Person, if any, who controls the Company
within the meaning of the 1933 Act or the 1934 Act (each, an “Indemnified Party”), against any Claim or Indemnified
Damages to which any of them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified
Damages arise out of or are based upon any Violation, in each case to the extent, and only to the extent, that such Violation
occurs in reliance upon and in conformity with written information furnished to the Company by such Investor expressly for use
in connection with such Registration Statement; and, subject to Section 6(c), such Investor shall reimburse the Indemnified Party
promptly as such expenses are incurred and due and are due and payable for any legal or other expenses reasonably incurred by
an Indemnified Party in connection with investigating or defending any such Claim; provided, however, that the indemnity agreement
contained in this Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts
paid in settlement of any Claim if such settlement is effected without the prior written consent of such Investor, which consent
shall not be unreasonably withheld or delayed; provided, further, however, that the Investor shall be liable under this Section
6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to such Investor as a result of
the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable
Securities by the Investors pursuant to Section 9.

 

(c) Promptly
after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall,
if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party
a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense
thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the
case may be; provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel
with the fees and expenses of not more than one counsel for all such Indemnified Person or Indemnified Party to be paid by the
indemnifying party, if, in the reasonable opinion of counsel retained by the Indemnified Person or Indemnified Party, as applicable,
the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate
due to actual or potential conflicts of interest between such Indemnified Person or Indemnified Party and any other party represented
by such counsel in such proceeding. In the case of an Indemnified Person, legal counsel referred to in the immediately preceding
sentence shall be selected by the Investors holding at least a majority in interest of the Registrable Securities included in
the Registration Statement to which the Claim relates. The Indemnified Party or Indemnified Person shall reasonably cooperate
with the indemnifying party in connection with any negotiation or defense of any such action or Claim by the indemnifying party
and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person
which relates to such action or Claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised
at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall
be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided, however,
that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without
the prior written consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement
or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party or Indemnified Person of a release from all liability in respect to such Claim or litigation and such settlement shall not
include any admission as to fault on the part of the Indemnified Party. Following indemnification as provided for hereunder, the
indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third
parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying
party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that the indemnifying
party is prejudiced in its ability to defend such action.

 

    - 14 -

     

    

 

(d) The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred; provided, that, the Indemnified Party shall promptly
reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified
Person is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review)
not to be entitled to indemnification hereunder.

 

(e) The
indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party
or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject
to pursuant to the law.

 

7. Contribution.

 

To
the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make
the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent
permitted by law; provided, however, that: (i) no Person involved in the sale of Registrable Securities which Person is guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with such sale shall be entitled
to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation;
and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the amount of net proceeds received
by such seller from the sale of such Registrable Securities pursuant to such Registration Statement.

 

8. Reports
Under the 1934 Act.

 

In
addition to the reporting and financial information requirements set forth in the Securities Purchase Agreement, and with a view
to making available to the Investors the benefits of Rule 144 promulgated under the 1933 Act or any other similar rule or regulation
of the SEC that may at any time permit the Investors to sell securities of the Company to the public without registration (“Rule
144”), the Company agrees from and after the sooner of the date the Company has a class of shares registered under Section
12(g) of the Exchange Act or is otherwise subject to reporting obligations under Section 13 or 15(d) of the Exchange Act, to:

 

(a) make
and keep public information available, as those terms are understood and defined in Rule 144;

 

    - 15 -

     

    

 

(b) file
with the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the 1934 Act so
long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the
applicable provisions of Rule 144; and

 

(c) furnish
to each Investor so long as such Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company,
if true, that it has complied with the reporting requirements of the 1933 Act and the 1934 Act and that it has satisfied the current
public information provisions set forth in Rule 144, and (ii) such other information as may be reasonably requested to permit
the Investors to sell such securities pursuant to Rule 144 without registration.

 

9. Assignment
of Registration Rights.

 

The
rights under this Agreement shall be automatically assignable by the Investors to any transferee of all or any portion of such
Investor’s Registrable Securities if: (i) the Investor agrees in writing with the transferee or assignee to assign such
rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment; (ii) the Company
is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the name and address of such
transferee or assignee, and (b) the securities with respect to which such registration rights are being transferred or assigned;
(iii) immediately following such transfer or assignment the further disposition of such securities by the transferee or assignee
is restricted under the 1933 Act or applicable state securities laws; (iv) at or before the time the Company receives the written
notice contemplated by clause (ii) of this sentence the transferee or assignee agrees in writing with the Company to be bound
by all of the provisions contained herein; and (v) such transfer shall have been made in accordance with the applicable requirements
of the Securities Purchase Agreement, and in an amount representing not less than $100,000 of Subscription Amount attributable
to such assigned Registrable Securities.

 

10. Amendment
of Registration Rights.

 

Provisions
of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company and the Required Holders; provided that any such
amendment or waiver that complies with the foregoing but that disproportionately, materially and adversely affects the rights
and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior
written consent of such adversely affected Investor. Any amendment or waiver effected in accordance with this Section 10 shall
be binding upon each Investor and the Company. No such amendment shall be effective to the extent that it applies to less than
all of the holders of the Registrable Securities. No consideration shall be offered or paid to any Person to amend or consent
to a waiver or modification of any provision of this Agreement unless the same consideration (other than the reimbursement of
legal fees) also is offered to all of the parties to this Agreement.

 

    - 16 -

     

    

 

11. Miscellaneous.

 

(a) A
Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the
same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from such record
owner of such Registrable Securities.

 

(b) Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be
in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); (iii) when sent, if sent by electronic mail; or (iv) one Business Day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the same. The addresses, facsimile numbers and email
addresses for such communications shall be:

 

If
to the Company:

 

MedyMatch
Technology Ltd.

76
Yigal Alon Street, Floor 5

Tel
Aviv, Israel 6706701

Attn:
Michael Rosenberg, co-Founder and CFO

Email:
mrosenberg@medymatch.com

 

With
a copy (for informational purposes only) to:

Meitar Liquornik Geva Leshem Tal, Law Offices

16
Abba Hillel Silver Road

Ramat
Gan 5250608, Israel

Attn:
David S. Glatt, Adv.

Fax:
(972) 3-610-3111

Email:
dglatt@meitar.com

 

If
to Legal Counsel:

 

Grushko
& Mittman, P.C.

515
Rockaway Avenue

Valley
Stream, NY 11581

Att:
Barbara R. Mittman, Esq.

Fax:
(212) 697-3575

Email:
barbara@grushkomittman.com

 

If
to an Investor, to its address, facsimile number and/or email address set forth on the Schedule of Investors attached hereto or
on the signature pages of the Securities Purchase Agreement, with copies to such Investor’s representatives as set forth
on the Schedule of Investors, or to such other address, facsimile number and/or email address to the attention of such other Person
as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such
change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B)
mechanically or electronically generated by the sender’s facsimile machine or email containing the time, date, recipient
facsimile number and an image of the first page of such transmission or (C) provided by a courier or overnight courier service
shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery
service in accordance with clause (i), (ii) or (iii) above, respectively.

 

    - 17 -

     

    

 

(c) Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or
remedy, shall not operate as a waiver thereof.

 

(d) All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the
State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING
OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(e) If
any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(f) This
Agreement, the other Transaction Documents (as defined in the Securities Purchase Agreement) and the instruments referenced herein
and therein constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There
are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This
Agreement, the other Transaction Documents and the instruments referenced herein and therein supersede all prior agreements and
understandings among the parties hereto with respect to the subject matter hereof and thereof.

 

(g) Subject
to the requirements of Section 9, this Agreement shall inure to the benefit of and be binding upon the permitted successors and
assigns of each of the parties hereto.

 

(h) The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

(i) This
Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute
one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile
transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

    - 18 -

     

    

 

(j) Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(k) All
consents and other determinations required to be made by the Investors pursuant to this Agreement shall be made, unless otherwise
specified in this Agreement, by the Required Holders.

 

(l) The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no
rules of strict construction will be applied against any party.

 

(m) This
Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not
for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(n) The
obligations of each Investor hereunder are several and not joint with the obligations of any other Investor, and no provision
of this Agreement is intended to confer any obligations on any Investor vis-à-vis any other Investor. Nothing contained
herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an
association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in
concert or as a group with respect to such obligations or the transactions contemplated herein.

 

(o) Legal
Counsel may resign as Legal Counsel on five (5) calendar days’ prior notice to the Company and Investors. 

 

*
* * * * *

[Signature
Page Follows]

 

    - 19 -

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	MEDYMATCH TECHNOLOGY LTD. 
	 	 	 
	 	By:	/s/
Michael Rosenberg
	 	 	Name: Michael Rosenberg
	 	 	Title:   co-Founder and CFO

  

[SIGNATURE
PAGE OF HOLDERS FOLLOWS]

 

    - 20 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

 

Name
of Investor: ______SOUTH FLORIDA BIOTECH VENTURES, LLC___________

 

Signature
of Authorized Signatory of Investor: ________/s/ Mark Groussman_________

 

Name
of Authorized Signatory: _________Mark Groussman_________________________

 

Title
of Authorized Signatory: ________Managing Member__________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: __________________________________________

 

Address
for Notice to Purchaser:445 W. 40th Street_______________________________

 

Miami
Beach, FL 33140__________________________

 

 

[SIGNATURE
PAGES CONTINUE]

 

    - 21 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

  

Name
of Investor: ______PALLADIUM CAPITAL ADVISORS LLC_______________

 

Signature
of Authorized Signatory of Investor: __________/s/ Joel Padowitz___________

 

Name
of Authorized Signatory: _________Joel Padowitz___________________________

 

Title
of Authorized Signatory: ________Managing Member__________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: ________(646) 390-6328_____________________

 

Address
for Notice to Purchaser:10 Rockefeller Plaza, Suite 909____________________

New
York, New York 10020______________________

 

 

 

[SIGNATURE
PAGES CONTINUE]

 

    - 22 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

  

Name
of Investor: ______HS Contrarian Investments, LLC_______________

 

Signature
of Authorized Signatory of Investor: _________/s/ John Steton____________

 

Name
of Authorized Signatory: _________John Stetson___________________________

 

Title
of Authorized Signatory: ________________________________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: __________________________________________

 

Address
for Notice to Purchaser:2300 E. Las Olas Blvd., 4th Floor, Fort Lauderdale, FL 33301

 

[SIGNATURE
PAGES CONTINUE]

 

    - 23 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

 

Name
of Investor: ______ATG Capital, LLC Retirement Plan                     

 

Signature
of Authorized Signatory of Investor: _________/s/ John Orourke___________

 

Name
of Authorized Signatory: _________John Orourke _________________________

 

Title
of Authorized Signatory: ________________________________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: __________________________________

 

Address
for Notice to Purchaser:808 Solar Isle, Fort Lauderdale, FL 33301

 

[SIGNATURE
PAGES CONTINUE]

 

    - 24 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

  

Name
of Investor: _____________________ATG Capital, LLC _______________

 

Signature
of Authorized Signatory of Investor: _________/s/ John Orourke___________

 

Name
of Authorized Signatory: _________John Orourke ___________________________

 

Title
of Authorized Signatory: ________________________________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: __________________________________________

 

Address
for Notice to Purchaser:2300 E. Las Olas Blvd., 2nd Floor, Fort Lauderdale, FL 3330

  

[SIGNATURE
PAGES CONTINUE]

 

    - 25 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

 

Name
of Investor: _____________Melechdavid, Inc., Retirement
Plan________

 

Signature
of Authorized Signatory of Investor: _______/s/ Mark Grousman____________

 

Name
of Authorized Signatory: _________Mark Grousman_________________________

 

Title
of Authorized Signatory: ________________________________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: __________________________________________

 

Address
for Notice to Purchaser:5154 La Gorce Drive, Miami Beach, FL 33140_______

  

[SIGNATURE
PAGES CONTINUE]

    - 26 -

     

    

 

[SIGNATURE
PAGE OF INVESTORS TO

MEDYMATCH
TECHNOLOGY LTD. RRA]

  

Name
of Investor: _____________________Delavaco Holdings, Inc___________

 

Signature
of Authorized Signatory of Investor: ______/s/ Catherine DeFrancesco_______

 

Name
of Authorized Signatory: _________Catherine DeFrancesco_________________________

 

Title
of Authorized Signatory: ________________________________________________

 

Email
Address of Authorized Signatory: _____________________________________________

 

Facsimile
Number of Authorized Signatory: __________________________________________

 

Address
for Notice to Purchaser:365 Bay Street Suite 840 Toronto, Ontario MH5 2V1

 

   

 

[SIGNATURE
PAGES CONTINUE]

  

    - 27 -

     

    

 

SCHEDULE
OF INVESTORS

  

	INVESTOR AND
    ADDRESS	 	PURCHASE
 PRICE
                                         and
 NOTE
                                         PRINCIPAL
 
	 	 	PRIVATE
 PURCHASE
 SHARES
	 
	SOUTH
                                         FLORIDA BIOTECH VENTURES, LLC
 445
                                         W. 40th Street
 Miami
                                         Beach, FL 33140
 Attn:
                                         Mark Groussman, Managing Member
 Fax:
 Email:
                                         mgman@bullhunterllc.com
	 	 	         	 	 	 	         
	PALLADIUM CAPITAL ADVISORS LLC 
10 Rockefeller Plaza,
    Suite 909 
New York, NY 10020 
Attn: Joel Padowitz, Managing Member 
Fax: (646) 390-6328 
Email: mhartstein@palladiumcapital.com	 	 	 	 	 	 	 	 
	HS CONTRARIAN INVESTMENTS, LLC 
2300 E. Las Olas
    Blvd., 4th Floor, Fort Lauderdale, FL 33301	 	 	 	 	 	 	 	 
	ATG Capital, LLC Retirement
    Plan 
808 Solar Isle, Fort Lauderdale, FL 33301	 	 	 	 	 	 	 	 
	ATG Capital, LLC 
2300
    E. Las Olas Blvd., 2nd Floor, Fort Lauderdale, FL 33301	 	 	 	 	 	 	 	 
	MELECHDAVID, INC. RETIREMENT PLAN 
5154 La Gorce
    Drive, Miami Beach, FL 33140	 	 	 	 	 	 	 	 
	DELAVACO HOLDINGS, INC. 
365 Bay Street Suite 840
    Toronto, Ontario MH5 2V1	 	 	 	 	 	 	 	 
	TOTAL	 	 	 	 	 	 	 	 

 

This
Schedule will be amended to include additional Investors who become Investors by participating in the Offering or becoming a permitted
assignee of an Investor.

 

    	 	A-1	 

     

    

 

EXHIBIT
A

FORM
OF NOTICE OF EFFECTIVENESS

OF REGISTRATION STATEMENT

 

Transfer
Agent

[RC]

 

Re:MedyMatch
Technology Ltd.

 

Ladies
and Gentlemen:

 

I
am counsel to MedyMatch Technology Ltd., a company incorporated under the laws of the State of Israel (the “Company”),
and have represented the Company in connection with that certain Securities Purchase Agreement, dated as of November [RC], 2017
(the “Securities Purchase Agreement”), entered into by and among the Company and the Investors named therein
(collectively, the “Holders”) pursuant to which the Company issued to the Holders convertible promissory notes
(“Notes”) convertible for Ordinary Shares of the Company, par value NIS 0.01 per share (the “Ordinary
Shares”) (the Ordinary Shares issuable pursuant to the terms of the Notes and Securities Purchase Agreement, collectively,
the “Conversion Shares”). Pursuant to the Securities Purchase Agreement, the Company also has entered into
a Registration Rights Agreement with the Holders (the “Registration Rights Agreement”) pursuant to which the
Company agreed, among other things, to register the resale of the Registrable Securities (as defined in the Registration Rights
Agreement), including the Conversion Shares issuable pursuant to the Securities Purchase Agreement under the Securities Act of
1933, as amended (the “1933 Act”). The description of the Registrable Securities are set forth on Schedule
A hereto [Selling Shareholder Table]. In connection with the Company’s obligations under the Registration Rights Agreement,
on [RC], 2017, the Company filed a Registration Statement on Form [RC] (File No. 333-_____________) (the “Registration
Statement”) with the Securities and Exchange Commission (the “SEC”) relating to the Registrable Securities
which names each of the Holders as a selling shareholder thereunder.

 

In
connection with the foregoing, I advise you that a member of the SEC’s staff has advised me by telephone that the SEC has
entered an order declaring the Registration Statement effective under the 1933 Act at [ENTER TIME OF EFFECTIVENESS]
on [ENTER DATE OF EFFECTIVENESS]. I have no knowledge, subsequent to such telephonic conversation with the SEC’s
staff, that any stop order suspending its effectiveness has been issued or that any proceedings for that purpose are pending before,
or threatened by, the SEC. Based on the foregoing, the Registrable Securities set forth on Schedule A hereto are available
for resale under the 1933 Act pursuant to the Registration Statement.

 

This
letter, unless and until subsequently revoked or modified orally by [RC], Esq. or in writing from any member of this firm (which
writing may include email correspondence), shall serve as our standing instruction to you that the Registrable Securities set
forth on Schedule A hereto are freely transferable by the Holders pursuant to the Registration Statement. You need not
require further letters from us to effect any future legend-free issuance or reissuance of Registrable Securities to the Holders
as contemplated by the Company’s Irrevocable Transfer Agent Instructions dated [●], 2017.

 

Very
truly yours,

 

By:_____________________

 

                                                        ,
Esq.

CC:Investors

    	 	A-2	 

     

    

 

EXHIBIT
B

 

SELLING
SHAREHOLDERS

 

The
Ordinary Shares being offered by the selling shareholders are those issued to the selling shareholders pursuant to the Securities
Purchase Agreement upon conversion of Notes. For additional information regarding the issuance of that Ordinary Shares, see “Private
Placement of Notes ” above. We are registering the Ordinary Shares in order to permit the selling shareholders to offer
the shares for resale from time to time. Except for the ownership of the Notes issued pursuant to the Securities Purchase Agreement,
the selling shareholders have not had any material relationship with us within the past three years.

 

The
table below lists the selling shareholders and other information regarding the beneficial ownership of the Ordinary Shares by
each of the selling shareholders as of ___________, 2018 including shares acquired by the selling shareholders from other shareholders
of the Company in connection with which registration rights were granted pursuant to the Registration Rights Agreement.

 

The
third column lists the Ordinary Shares being offered by this prospectus by the selling shareholders.

 

In
accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the
resale of at least the sum of (i) the number of Ordinary Shares issued upon conversion of the Notes as of the Trading Day immediately
preceding the date the registration statement is initially filed with the SEC, and (ii) the maximum number of Ordinary Shares
issued as of the Trading Day immediately preceding the date the registration statement is initially filed with the SEC. The fourth
column assumes the sale of all of the shares offered by the selling shareholders pursuant to this prospectus.

 

The
selling shareholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

 

	Name of Selling Shareholder	 	 	Number of Ordinary Shares Owned Prior to Offering	 	 	Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus	 	 	Number of Ordinary Shares Owned After Offering	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 		 	 	 		 	 	 		 	 	 		 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

    B-1

     

    

 

PLAN
OF DISTRIBUTION

 

We
are registering the Ordinary Shares issued upon conversion of the notes to permit the resale of these Ordinary Shares by the holders
of such notes from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the
selling shareholders of the Ordinary Shares. We will bear all fees and expenses incident to our obligation to register the Ordinary
Shares.

 

The
selling shareholders may sell all or a portion of the Ordinary Shares beneficially owned by them and offered hereby from time
to time directly or through one or more underwriters, broker-dealers or agents. If the Ordinary Shares are sold through underwriters
or broker-dealers, the selling shareholders will be responsible for underwriting discounts or commissions or agent’s commissions.
The Ordinary Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale,
at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which
may involve crosses or block transactions,

 

	 	●	on
    any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

 

	 	●	in
    the over-the-counter market;

 

	 	●	in
    transactions otherwise than on these exchanges or systems or in the over-the-counter market;

 

	 	●	through
    the writing of options, whether such options are listed on an options exchange or otherwise;

 

	 	●	ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

	 	●	block
    trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;

 

	 	●	purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;

 

	 	●	an
    exchange distribution in accordance with the rules of the applicable exchange;

 

	 	●	privately
    negotiated transactions;

 

	 	●	sales
    pursuant to Rule 144;

 

	 	●	broker-dealers
    may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share;

 

	 	●	a
    combination of any such methods of sale; and

 

	 	●	any
    other method permitted pursuant to applicable law.

 

    B-2

     

    

 

If
the selling shareholders effect such transactions by selling Ordinary Shares to or through underwriters, broker-dealers or agents,
such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from
the selling shareholders or commissions from purchasers of the Ordinary Shares for whom they may act as agent or to whom they
may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may
be in excess of those customary in the types of transactions involved). In connection with sales of the Ordinary Shares or otherwise,
the selling shareholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the
Ordinary Shares in the course of hedging in positions they assume. The selling shareholders may also sell Ordinary Shares short
and deliver Ordinary Shares covered by this prospectus to close out short positions and to return borrowed shares in connection
with such short sales. The selling shareholders may also loan or pledge Ordinary Shares to broker-dealers that in turn may sell
such shares.

 

The
selling shareholders may pledge or grant a security interest in some or all of the Ordinary Shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Ordinary Shares
from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision
of the Securities Act of 1933, as amended, amending, if necessary, the list of selling shareholders to include the pledgee, transferee
or other successors in interest as selling shareholders under this prospectus. The selling shareholders also may transfer and
donate the Ordinary Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest
will be the selling beneficial owners for purposes of this prospectus.

 

The
selling shareholders and any broker-dealer participating in the distribution of the Ordinary Shares may be deemed to be “underwriters”
within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer
may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the Ordinary
Shares is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of Ordinary
Shares being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts,
commissions and other terms constituting compensation from the selling shareholders and any discounts, commissions or concessions
allowed or reallowed or paid to broker-dealers.

 

Under
the securities laws of some states, the Ordinary Shares may be sold in such states only through registered or licensed brokers
or dealers. In addition, in some states the Ordinary Shares may not be sold unless such shares have been registered or qualified
for sale in such state or an exemption from registration or qualification is available and is complied with.

 

There
can be no assurance that any selling shareholder will sell any or all of the Ordinary Shares registered pursuant to the registration
statement, of which this prospectus forms a part.

 

The
selling shareholders and any other person participating in such distribution will be subject to applicable provisions of the Securities
Exchange Act of 1934, as amended, and the rules and regulations thereunder, including, without limitation, Regulation M of the
Exchange Act, which may limit the timing of purchases and sales of any of the Ordinary Shares by the selling shareholders and
any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the Ordinary
Shares to engage in market-making activities with respect to the Ordinary Shares. All of the foregoing may affect the marketability
of the Ordinary Shares and the ability of any person or entity to engage in market-making activities with respect to the Ordinary
Shares.

 

We
will pay all expenses of the registration of the Ordinary Shares pursuant to the registration rights agreement, estimated to be
$[     ] in total, including, without limitation, Securities and Exchange Commission filing fees and
expenses of compliance with state securities or “blue sky” laws; provided, however, that a selling shareholder will
pay all underwriting discounts and selling commissions, if any. We will indemnify the selling shareholders against liabilities,
including some liabilities under the Securities Act, in accordance with the registration rights agreements, or the selling shareholders
will be entitled to contribution. We may be indemnified by the selling shareholders against civil liabilities, including liabilities
under the Securities Act, that may arise from any written information furnished to us by the selling shareholder specifically
for use in this prospectus, in accordance with the related registration rights agreement, or we may be entitled to contribution.

 

Once
sold under the registration statement, of which this prospectus forms a part, the Ordinary Shares will be freely tradable in the
hands of persons other than our affiliates.

 

 

B-3Exhibit 10.7

 

OMNIBUS AMENDMENT
AGREEMENT

 

THIS OMNIBUS AMENDMENT
AGREEMENT (this “Amendment”), is made as of March 23, 2018, between MaxQ AI Ltd. (f/k/a MedyMatch Technology
Ltd.), a company incorporated under the laws of the State of Israel (the “Company”), and South Florida Biotech
Ventures LLC (including its successors and permitted assigns, “South Florida”). Capitalized terms used but
not defined herein shall have the meaning ascribed to them in the SPA (as defined below).

 

WHEREAS, the
Company and South Florida entered into that certain Securities Purchase Agreement (the “SPA”), Registration
Rights Agreement (the “RRA”) and Security Agreement (Fixed Charge) and Security Agreement (Floating Charge)
(the “Security Agreements”), all dated December 29, 2017; and

 

WHEREAS, the
Company and South Florida constitute the required majority to amend the terms of the SPA and RRA in accordance with the terms thereof;
and

 

WHEREAS, the
Company and South Florida wish to amend certain provisions of the SPA and RRA and to clarify certain matters of the Security Agreements,
as more thoroughly described herein; and

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties hereto hereby agree as follows:

 

	1.	Amendment to the SPA.

 

	 	1.1.	Part (e) of the definition of “Exempt Issuance” under Section 1.1 of the SPA shall be replaced in its entirety with the following (additions are bold and underlined and deletions are struck through):

 

“(e) additional Notes
which may be issued on or before the Termination Date to South Florida Biotech Ventures LLC in the principal amount of $125,000,
to Melechdavid, Inc.Exigent as a Purchaser hereunder in the principal amount of up to $1,500,000$125,000,
to HS Contrarian Investments LLC in the principal amount of $250,000, and to Alpha Capital Anstalt in the principal amount of $1,000,000
on the same terms and conditions as the Offering and when issued and paid for will be deemed to constitute part of the Offering,
including but not limited to with respect to security interests ranking pari passu among all Purchasers (including
Exigent) and registration rights pursuant to the Purchaser Registration Rights Agreement except that (i)
Exigent will receive the registration rights under the Exigent Registration Rights Agreement, and (ii) the Conversion
Price (as defined in the Note) (i.e. pre-Qualified Offering, pre-money valuation of the Company) shall be $27.30, subject to adjustment
for share splits and other recapitalization events.”

 

	 	1.2.	The definition of “Exigent Option” under Section 1.1. of the SPA shall be deleted in its entirety.

 

	 	1.3.	The following definition of “South Florida Option” shall be added to Section 1.1. of the SPA immediately after the definition of “Security Agreements”:

 

“South Florida
Option” shall mean the rights available to South Florida Biotech Ventures LLC, Melechdavid, Inc., HS Contrarian Investments
LLC and Alpha Capital Anstalt as described in part (e) of the definition of Exempt Issuance.

 

    	 	1	 

     

    

 

	 	1.4.	Section 2.1 of the SPA shall be replaced in its entirety with the following (additions are bold and underlined and deletions are struck through):

 

“2.1 Closing.
On the Closing Dates, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, through Palladium,
and the Purchasers, severally and not jointly, agree to purchase, an aggregate of $4,320,000 (inclusive of the Palladium Notes,
as defined below, but exclusive of any amounts under Notes issued pursuant to the South Florida Option) of principal
amount of Notes, each such purchase and sale being a “Closing”. An additional Note representing the placement
agent fee payable to Palladium as described on Schedule 3.1(r) will be issued on eachthe
Closing Date for the placement agent fee payable to Palladium with respect to suchthe Closing (each
a “Palladium Note” and collectively, “Palladium Notes”), provided that no fee shall
be due to Palladium with respect to the South Florida Option. The Notes issuable to Palladium will be held by the Escrow
Agent and delivered to Palladium only upon the closing of the Qualified Offering. Each Purchaser shall deliver to the Company such
Purchaser’s Subscription Amount, and the Company shall deliver to each Purchaser its respective Note, and the Company and
each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at a Closing. Upon satisfaction of the covenants
and conditions set forth in Sections 2.2 and 2.3, each Closing shall occur at the offices of Purchaser Counsel or such other location
as the parties shall mutually agree. Notwithstanding anything herein to the contrary, the initial Closing must take place on or
before December 27, 2017. The Closing Date for the final Closing if Exigent elects to exercise any portion of the Exigent
option described in item (e) of the definition of Exempt Issuance, shall occur on or before March 29, 2018 (the “Termination
Date”). With respect to any Closing not held on or before the Termination Date, the Escrow Agent shall cause all subscription
documents and funds, if any, to be returned, without interest or deduction to each prospective Purchaser. Notwithstanding the date
of any Closing subsequent to the initial Closing, all time effective clauses in the Transaction Documents shall commence on the
initial Closing Date and the Transaction Documents will be deemed modified mutatis mutandis in connection with such subsequent
Closings, if any, including with respect to the exercise of the South FloridaExigent Option. The
Maturity Date (as defined in the Notes) of the Notes issued at all Closings subsequent to the initial Closing shall be the same
as the Maturity Date of the Notes issued at the initial Closing. No sale of Notes may be made pursuant to this Agreement except
pursuant to the Company’s agreement with Palladium as placement agent pursuant to a written agreement between the Company
and Palladium. The South FloridaExigent Option may be exercised, in one or more occasions,
only after ten Business Days’ prior notice to the Purchasers who must receive details of the exercise, the principal amount
in respect of which the Note is to be issued, and copies of the Transaction Documents to be employed therewith; with respect
to Notes issuable pursuant to the South Florida Optionto Exigent hereunder, Exhibit A shall
be amended to reflect the Conversion Price per partitem (e)(2) of the definition of “Exempt
Issuance”.

 

	 	1.5.	The parties to this Amendment agree that Disclosure Schedules as of the date of this Amendment shall be in accordance with amended Schedule 3, which forms part of this Amendment.

 

	 	1.6.	The persons and entities listed as Lock Up Agreement providers under Schedule 4.16 of the SPA shall be amended in accordance with the amended Schedule 4.16, which forms part of this Amendment. The parties to this Amendment agree that the Lock Up Agreements previously signed by the parties shall apply with respect to the amount of shares listed on the amended Schedule 4.16, including shares to be issued upon conversion of Notes to be issued under this Amendment.

 

    	 	2	 

     

    

 

	2.	Amendment to the RRA.

 

	 	2.1.	The definition of “Initial Registrable Securities” under Section 1(r) of the RRA shall be replaced in its entirety with the following (additions are bold and underlined and deletions are struck through):

 

“Initial Registrable
Securities” means (i) the Conversion Shares issuable upon conversion of the Notes issued in connection with eachthe
Closing under the Securities Purchase Agreement, (ii) the Conversion Shares issuable upon conversion of the
Notes issued in connection with South Florida Option as defined in the Securities Purchase Agreement, (iii)
the Ordinary Shares described on the Schedule of Investors under the heading “Private Purchase Shares”, and (ivii)
any capital stock of the Company issued or issuable with respect to the Notes and Conversion Shares and Private Purchase Shares
as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise without regard to any
limitations on conversion of the Notes including interest which could accrue through six months after the issue date of the Notes;
but excluding any Ordinary Shares held by or issuable to Exigent.

 

	3.	Clarification with respect to the Security Agreements

 

	 	3.1.	The parties hereby agree that any additional Notes to be issued pursuant to the South Florida Option shall be deemed Notes under the Security Agreements and the Purchasers and the Company shall cause to be made at the Company’s expense all filings necessary or appropriate to memorialize and protect the rights of Purchasers under the Security Agreements.

 

	4.	Fees and Expenses.

 

	 	4.1.	Each party hereto shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Amendment; provided that subject to consummation of an additional Closing under the SPA, the Company shall pay the costs actually incurred by Palladium in connection with the investment contemplated by the SPA and this Amendment (including legal costs), up to the maximum amount of US$10,000 and the legal fees, costs and expenses referred to in Section 3.1. Reimbursement may be made by way of direct payment to Palladium’s advisors.

 

	5.	Exercise of Option and Additional Investment.

 

	 	5.1.	South Florida hereby exercises the South Florida Option and subscribes for an additional $250,000 principal Note amount pursuant to the SPA. The Company and South Florida will take such actions and enter into additional agreements as necessary to effectuate the foregoing option exercise and additional subscription.

 

	 	5.2.	HS Contrarian Investments LLC hereby exercises the South Florida Option and subscribes for an additional $250,000 principal Note amount pursuant to the SPA. The Company and HS Contrarian Investments LLC will take such actions and enter into additional agreements as necessary to effectuate the foregoing option exercise and additional subscription.

 

	 	5.3.	Alpha Capital Anstalt hereby exercises the South Florida Option and subscribes for an additional $1,000,000 principal Note amount pursuant to the SPA. The Company and Alpha Capital Anstalt will take such actions and enter into additional agreements as necessary to effectuate the foregoing option exercise and additional subscription.

 

	6.	Escrow.

 

	 	6.1.	Escrow Closing. The parties hereto agree that a Closing with respect to the South Florida Option exercise may take place directly between the parties hereto and not pursuant to the Escrow Agreement.

 

	7.	Miscellaneous.

 

	 	7.1.	Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Amendment (other than those mandatorily subject to Israeli law and which may not be waived under Israeli law) shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof except as to corporate law matters which are specifically required by the laws of the State of Israel to be governed by the laws of the State of Israel.

 

    	 	3	 

     

    

 

	 	7.2.	Entire Agreement. This Amendment together with the SPA, Security Agreements and all exhibits and ancillaries hereto and thereto, constitute the full and entire agreement, covenants, promises and understandings between the parties hereto with respect to the subject matter hereof, and supersede any and all prior agreements, understandings, promises and representations made by all or some of the parties (or by either party to the other), written or oral, concerning the subject matter hereof and the terms applicable hereto. In the event of inconsistency between the terms of this Amendment and the Security Agreements, the terms of this Amendment shall prevail.

 

	 	7.3.	Amendment & Waivers. Any term of this Amendment may be amended and the severance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company, the Purchasers representing the Majority in Interest under the SPA.

 

	 	7.4.	Counterparts This Amendment may be executed by multiple counterparts (including facsimile counterparts), each of which shall be original as against the party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.

 

[REST OF THIS PAGE LEFT INTENTIONALLY BLANK]

 

    	 	4	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Omnibus Amendment Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

COMPANY:

 

MAXQ AI Ltd. 

 

	/s/ Michael Rosenberg	 
	By: 	Michael Rosenberg	 
	Its: 	Chief Financial Officer	 

 

PURCHASERS:

 

South Florida Biotech
Ventures LLC

 

	/s/ Mark Grossman	 
	By: 	Mark Grossman	 
	Its: 	Managing Member	 

  

HS CONTRARIAN INVESTMENTS
LLC

  

	/s/ John Stetson	 
	By: 	John Stetson	 
	Its: 	Managing Member	 

  

ALPHA CAPITAL ANSTALT

  

	/s/ Konrod Ackermann	 
	By: 	Konrod Ackermann	 
	Its: 	Director	 

  

MELECHDAVID, INC.

  

	/s/ Mark Grossman	 
	By: 	Mark Grossman	 
	Its: 	President	 

  

ACKNOWLEDGED AND AGREED:

  

GRUSHKO & MITTMAN, P.C. AS

ESCROW AGENT

 

	By: 	/s/ Grushko & Mittman, P.C.	 

  

EXIGENT MANAGEMENT LTD.

 

(With respect to the waiver
of the Exigent Option

(as defined in the SPA, prior to this Amendment))

 

	By: 	/s/ ELD	 

  

[MaxQ AI Ltd. / Signature Page to Omnibus
Amendment Agreement] 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]